Stock Events

Stock Events

Corbus Pharmaceuticals 

$10.59
178
+$0.45+4.44% Friday 20:00

Statistics

Day High
11
Day Low
10.15
52W High
19.36
52W Low
5.8
Volume
546,300
Avg. Volume
-
Mkt Cap
185.89M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

12MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-1.9
-1.53
-1.15
-0.78
Expected EPS
-1.206114
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-80.42MNet Income

Analyst Ratings

55Average Price Target
The highest estimate is 57.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CRBP. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Abbvie
ABBV
Mkt Cap368.57B
AbbVie has a strong portfolio in immunology and inflammatory diseases, overlapping with Corbus's therapeutic areas.
Gilead Sciences
GILD
Mkt Cap170.84B
Gilead Sciences has a broad focus on life-threatening diseases, including inflammatory disorders, making it a competitor in the same therapeutic space as Corbus.
AMGEN
AMGN
Mkt Cap191.53B
Amgen has a diverse biotechnological portfolio, including treatments for inflammatory diseases, competing with Corbus's market.
Bristol-Myers Squibb
BMY
Mkt Cap122.85B
Bristol Myers Squibb offers several products in the area of immune system modulation and inflammation, competing with Corbus's research and product development.
Pfizer
PFE
Mkt Cap156.77B
Pfizer has a wide range of products targeting inflammatory and autoimmune diseases, directly competing with Corbus's focus areas.
Regeneron Pharmaceuticals
REGN
Mkt Cap79.35B
Regeneron Pharmaceuticals specializes in medicines for serious medical conditions, including inflammatory diseases, making it a competitor to Corbus.
Vertex Pharmaceuticals
VRTX
Mkt Cap112.22B
Vertex Pharmaceuticals invests in creating transformative medicines for people with serious diseases, including those related to inflammation, competing with Corbus's mission.
Incyte
INCY
Mkt Cap19.47B
Incyte Corporation focuses on the discovery, development, and commercialization of proprietary therapeutics, including for inflammation, competing with Corbus.
Merck
MRK
Mkt Cap294.39B
Merck operates in various therapeutic areas, including immunology and inflammation, making it a competitor to Corbus Pharmaceuticals.

About

Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity. The company was incorporated in 2009 and is headquartered in Norwood, Massachusetts.
Show more...
CEO
Dr. Yuval Cohen Ph.D.
Employees
28
Country
United States
ISIN
US21833P3010

Listings

STU
DE
3371.STU
MU
DE
3371.MU
LSE
GB
0SZI.LSE
F
DE
3371.F

0 Comments

Share your thoughts

FAQ

What is Corbus Pharmaceuticals stock price today?▼
The current price of CRBP is $10.59 USD — it has increased by +4.44% in the past 24 hours. Watch Corbus Pharmaceuticals stock price performance more closely on the chart.
What is Corbus Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Corbus Pharmaceuticals stocks are traded under the ticker CRBP.
Is Corbus Pharmaceuticals stock price growing?▼
CRBP stock has risen by +4.03% compared to the previous week, the month change is a +23.14% rise, over the last year Corbus Pharmaceuticals has showed a +75.62% increase.
What is Corbus Pharmaceuticals market cap?▼
Today Corbus Pharmaceuticals has the market capitalization of 185.89M
When is the next Corbus Pharmaceuticals earnings date?▼
Corbus Pharmaceuticals is going to release the next earnings report on May 12, 2026.
What were Corbus Pharmaceuticals earnings last quarter?▼
CRBP earnings for the last quarter are -1.25 USD per share, whereas the estimation was -1.52 USD resulting in a +17.64% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Corbus Pharmaceuticals revenue for the last year?▼
Corbus Pharmaceuticals revenue for the last year amounts to 0 USD.
What is Corbus Pharmaceuticals net income for the last year?▼
CRBP net income for the last year is -80.42M USD.
How many employees does Corbus Pharmaceuticals have?▼
As of April 20, 2026, the company has 28 employees.
In which sector is Corbus Pharmaceuticals located?▼
Corbus Pharmaceuticals operates in the Health & Wellness sector.
When did Corbus Pharmaceuticals complete a stock split?▼
The last stock split for Corbus Pharmaceuticals was on February 14, 2023 with a ratio of 1:30.
Where is Corbus Pharmaceuticals headquartered?▼
Corbus Pharmaceuticals is headquartered in Norwood, United States.